secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001558370-22-013401
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 2.05, 3.03, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems Q2 revenue $3.9M; lowers FY22 outlook to ≥$17M, cuts 20% workforce
--------------------------------------------------------------------------------

- Q2 commercial revenue $3.9M vs $5.7M YoY; net loss $13.1M ($0.31 loss per share).
- Full-year 2022 revenue guidance reduced to at least $17.0M (from prior higher outlook); expects 3-5 system placements in H2.
- Implements restructuring: 20% workforce reduction, $1.5M charge in Q3, expected $8-9M annualized cost savings.
- CCO Andy Keys departs; CEO Robert Spignesi assumes commercial leadership.
- Board launches strategic alternatives review; rejects Kennedy Lewis $5.00/share acquisition proposal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000155837022013401/0001558370-22-013401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000155837022013401/rpid-20220811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer